Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy

Circulation. 1991 Mar;83(3):937-44. doi: 10.1161/01.cir.83.3.937.

Abstract

Background: It has been suggested that thrombolysis in a feedback reaction may generate pro-coagulant activities.

Methods and results: Fifty-five patients were treated with urokinase-preactivated prourokinase (n = 35) or tissue-type plasminogen activator (n = 20) for acute myocardial infarction and underwent coronary angiography at 90 minutes and at 24-36 hours into thrombolysis, and fibrinogen (Ratnoff-Menzie), D-dimer (ELISA) and thrombin-antithrombin III complex levels (ELISA) were measured. Primary patency was achieved in 39 patients (70.9%), 13 of whom (33.3%) suffered early reocclusion. Nonsignificant decreases in fibrinogen levels were observed while D-dimer levels increased +3,008 +/- 4,047 micrograms/l (p less than 0.01), differences not being significant in respect to the thrombolytic agents or to the clinical course. In contrast, while thrombin-antithrombin III complex levels decreased -4.4 +/- 13.0 micrograms/l in patients with persistent patency, they increased +7.5 +/- 13.6 micrograms/l in case of nonsuccessful thrombolysis (p less than 0.02) and +11.9 +/- 23.8 micrograms/l in case of early reocclusion (p less than 0.001). For patients with thrombin-antithrombin III complex levels greater than 6 ng/l 120 minutes into thrombolysis, the unfavorable clinical course was predicted with 96.2% sensitivity and 93.1% specificity.

Conclusion: Generation of thrombin, occurring during thrombolysis, is a major determinant for the success of therapy and thrombin-antithrombin III levels may serve as predictors for the short-term prognosis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antithrombin III / analysis*
  • Enzyme Precursors / therapeutic use
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Peptide Hydrolases / analysis*
  • Plasminogen Activators / therapeutic use*
  • Prospective Studies
  • Thrombin / analysis*
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Enzyme Precursors
  • Fibrinolytic Agents
  • antithrombin III-protease complex
  • Antithrombin III
  • Peptide Hydrolases
  • Plasminogen Activators
  • Thrombin
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator